Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica has announced the appointment of Lucinda Crabtree as the new Chief Financial Officer and Board member, effective 2 September 2024, replacing Stuart Paynter who is stepping down after seven years. Crabtree brings extensive financial and biopharmaceutical industry experience to the role, having held CFO positions at MorphoSys AG and Autolus Therapeutics, and previously worked in investment at several prestigious institutions. The leadership transition comes as the company, a leading cell and gene therapy CDMO, positions itself for its next growth phase in the expanding market.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
